Advanced Biliary Tract Cancers: Novel Biomarker Strategies
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Novel Agents Being Explored in Advanced Biliary Tract Cancers
Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
Sequencing Therapy in Patients With Advanced Biliary Tract Cancers
In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations
Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy
Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
An Overview of Systemic Therapy for Advanced Biliary Tract Cancers
Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers
Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
What is the Role of Transplant in Early-Stage Biliary Tract Cancers?
Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
Dr. Pillai on Sequential Treatment in HCC
Anjana Pillai, MD, discusses sequential treatment in hepatocellular carcinoma.
Dr. Pillai on the Importance of Multidisciplinary Discussion in HCC
Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512